Table 6.
Multivariate analysisfor the effect of clinicopathologic parameters and SHP2expression on overall survival
| Clinicopathologic parameter | Hazard Ratio (95% CI) | p-value |
|---|---|---|
| Age(per 1-year ) | 1.037 (1.030–1.044) | <0.0001 |
| Tumor size | ||
| pT1 (reference) | 1 | |
| pT2 | 1.619 (1.247–2.101) | 0.0003 |
| pT3 | 2.139 (1.482–3.089) | <0.0001 |
| pT4 | 2.269 (1.639–3.143) | <0.0001 |
| Lymph node involvement | ||
| pN1 (reference) | 1 | |
| pN1 | 1.420 (1.165–1.732) | 0.0005 |
| pN2 | 2.602 (1.969–3.440) | <0.0001 |
| Tumor grade | ||
| BRE grade 1 (reference) | 1 | |
| 2 | 1.582 (1.196–2.092) | 0.0013 |
| 3 | 2.527 (1.889–3.381) | <0.0001 |
| Intrinsic subtypes | ||
| Luminal A | 1 | |
| Luminal B (HER2−) | 1.080 (0.796–1.465) | 0.6205 |
| Luminal B (HER2+) | 1.268 (0.870–1.848) | 0.2159 |
| HER2 type | 1.169 (0.774–1.764) | 0.4579 |
| Basal-like | 1.941 (1.369–2.752) | 0.0002 |
| SHP2 expression, all cases* | ||
| 1.239 (1.038–1.480) | 0.0177 |
*
Interaction between SHP2 expression and intrinsic subtypes not significant (p=0.91)